Showing posts with label Research. Show all posts
Showing posts with label Research. Show all posts

Friday, August 23, 2013

Pediatric Research Bill: Obamacare’s Road to Rationing?

Later this month, the House of Representatives could consider legislation regarding pediatric research.[1] Legislation regarding this issue (H.R. 1724) was first introduced in April, and a new version of the bill (H.R. 2019) was introduced in May.

Although largely similar, H.R. 1724 would require the director of the National Institutes of Health (NIH) to provide a justification for any existing grants studying health economics, and would prohibit new grants until “a federal law has been enacted authorizing the National Institutes of Health to use funding specifically for health economics research.”[2] Press reports indicate that H.R. 2019 excludes the restrictions included in H.R. 1724 “in order to please Democrats who favor the research.”[3]

This is a mistake. The House should ensure that H.R. 1724’s proposed restrictions on health economics research remain in any NIH-related legislation that comes to the House floor. To do otherwise would provide tacit approval to Obamacare’s road to government-rationed health care.

Proposed Restriction a Necessary Protection

The provision omitted from H.R. 2019 would have instituted an important and necessary protection on taxpayer-funded research on cost-effectiveness in health care. In recent years, the federal government has funded numerous such studies. For instance, a June 2011 Government Accountability Office report examining projects funded by the “stimulus” highlighted NIH grants studying the cost-effectiveness of various medical treatments, including:

“A Comprehensive Model to Assess the Cost-Effectiveness of Patient Navigation,”“Cost-Effectiveness of Hormonal Therapy for Clinically Localized Prostate Cancer;”“Clinical and Cost-Effectiveness of Biologics in Rheumatoid Arthritis,” and“Cost-Effectiveness of HIV-Related Mental Health Interventions.”[4]

Liberals Favor Cost-Effectiveness Research

Setting aside the wisdom of using taxpayer funds to examine the cost-effectiveness of various treatments, such research could eventually be used to deny patients access to certain kinds of care. Quotes from key policymakers reveal how some would use cost-effectiveness research as a way for government bureaucrats to block access to treatments that are deemed too costly:

Former Senator Tom Daschle (D–SD), President Obama’s first choice for Secretary of Health and Human Services, wrote in 2008 that “we won’t be able to make a significant dent in health-care spending without getting into the nitty-gritty of which treatments are the most clinically valuable and cost effective. That means taking a harder look at the real costs and benefits of new drugs and procedures.”[5]In a 2009 interview with The New York Times, President Obama argued that “the chronically ill and those toward the end of their lives are accounting for potentially 80 percent of the total health care bill out here.… There is going to have to be a very difficult democratic conversation that takes place.”[6]Former Medicare Administrator Dr. Donald Berwick, in his infamous 2009 interview, strongly argued in favor of taxpayer-funded cost-effectiveness research when stating that “the decision is not whether or not we will ration care—the decision is whether we will ration with our eyes open.”[7]

Lawmakers have already expressed their desire to use cost-effectiveness research to restrict access to certain treatments. A report prepared by the House Appropriations Committee in 2009, discussing “stimulus” funding for the types of projects highlighted above, noted that thanks to the research funding, “those items, procedures, and interventions that are most effective to prevent, control, and treat health conditions will be utilized, while those that are found to be less effective and in some cases more expensive will no longer be prescribed.”[8]

Road to Rationing

Although research comparing the relative merits and costs of medical treatments may sound appealing, past experience has demonstrated that such research can, and often is, used as a blunt tool by governments to restrict access to certain kinds of care. At a time when genetic advances have opened the door to personalized medical treatments, Obamacare has moved health policy in the opposite direction, expanding the federal bureaucracy in an attempt to micromanage the health care system.[9]

Imposing the restrictions on cost-effectiveness research included in H.R. 1724 would represent a good first step in restoring the balance between federal bureaucrats and patients.

—Chris Jacobs is Senior Policy Analyst in the Center for Health Policy Studies at The Heritage Foundation.


[2]The Kids First Research Act of 2013, H.R. 1724, § 4.

[3]Newhauser, “Mindful of Previous Defeat.”

[4]U.S. Government Accountability Office, HHS Research Awards: Use of Recovery Act and Patient Protection and Affordable Care Act Funds for Comparative Effectiveness Research, GAO-11-712R, June 14, 2011, http://www.gao.gov/new.items/d11712r.pdf (accessed June 13, 2013).

[5]Tom Daschle, Scott Greenberger, and Jeanne Lambrew, Critical: What We Can Do about the Health Care Crisis (New York: Thomas Dunne Books, 2008), pp. 172–173.


View the original article here

Tuesday, July 2, 2013

RESEARCH ALERT-Galena Biopharma: Needham starts with buy rating

March 25 (Reuters) - Galena Biopharma Inc :

* Needham starts with buy rating; price target of $3.50

For a summary of rating and price target changes on U.S. companies:

Reuters Eikon users, click on

Reuters 3000Xtra users, double-click

Reuters Station users, click .1568

For a summary of rating and price target changes on Canadian companies:

Reuters Eikon users, click on

Reuters 3000Xtra users, double-click

Reuters Station users, click .4899

((nyc.equities.newsroom@reuters.com); (Reuters Messaging: saqib.ahmed.thomsonreuters.com@reuters.net) ((Bangalore Newsroom +91 80 4135 5800; within U.S. +1 646 223 8780))


View the original article here

Saturday, June 29, 2013

RESEARCH ALERT-Array BioPharma: Piper Jaffray raises to overweight

March 25 (Reuters) - Array Biopharma Inc :

* Piper Jaffray raises to overweight from neutral; target price to $7 from $4

For a summary of rating and price target changes on U.S. companies:

Reuters Eikon users, click on

Reuters 3000Xtra users, double-click

Reuters Station users, click .1568

For a summary of rating and price target changes on Canadian companies:

Reuters Eikon users, click on

Reuters 3000Xtra users, double-click

Reuters Station users, click .4899

((nyc.equities.newsroom@reuters.com); (Reuters Messaging: saqib.ahmed.thomsonreuters.com@reuters.net) ((Bangalore Newsroom +91 80 4135 5800; within U.S. +1 646 223 8780))


View the original article here

Friday, June 14, 2013

*RESEARCH ALERT-Galena Biopharma: Maxim Group raises target price

Sorry, I could not read the content fromt this page.

View the original article here

Claims That There Is No Research About The Effectiveness Of Ex-Gay Therapy Are True

Christopher Doyle

Advocates of so-called ex-gay therapy (often referred to as sexual orientation change efforts, or SOCE) are not pleased that the New Jersey legislature is seriously considering a ban on the treatment for minors. The increasingly vocal Christopher Doyle, who works with the infamously disavowed therapist Richard Cohen, penned a reaction for Christian Post asking, “Where is the tolerance” for people who are ex-gay? But his post actually helps outline many of the reasons nobody humors ex-gay therapy.

For example, he reiterated the canard that sexual abuse causes people to be gay:

That’s right, even if your child was sexually abused by a pedophile such as Jerry Sandusky and develops homosexual inclinations as a consequence, he/she may not be able to receive Sexual Orientation Change Effort (SOCE) therapy from a highly educated and skilled professional counselor, social worker, or psychologist. Why, you ask? According to the office of Massachusetts State Representative Carl Sciortino (D), because SOCE is an “archaic vestige of homophobia” and should be banned.

This argument is actually just an inverse of conservatives’ tired claim that gay men are more likely to be pedophiles. Because boys are often the victim of abuse in high-visibility institutions like the Catholic Church, the Boy Scouts of America, or athletic teams and their abusers are male, conservatives conclude that the perpetrator must be gay, even though pedophilia has nothing to do with sexual orientation. Likewise, ex-gay advocates claim that any boy who was once abused by a man and later realizes he is gay must have somehow been swayed or corrupted by the abuse itself. There is nothing to reinforce this conclusion, however, except conservatives’ ability to prey on the vulnerability of these traumatized young people.

Doyle goes on to claim that there is no research available about the outcomes of ex-gay therapy for adolescents:

The problem with this conspiracy is this: There is NOT ONE scientific study that contains any hard data on the outcomes of SOCE for adolescents. Not one!

So when I contacted the offices proposing a ban on SOCE therapies and asked them to cite studies that show “harmful” outcomes for adolescents, they could only point me to position statements from liberal trade organizations, which are known for their one-hand clapping viewpoint, strictly pro-gay and anti-ex-gay. If these organizations were made up of objective scientists that looked at all the evidence, such legislation would not be allowed anywhere.

Doyle unsurprisingly demonstrates a complete ineptness for understanding scientific rigor. His claim is not entirely wrong: there is not one scientific study that contains any hard data on the outcomes of SOCE for anybody. That’s because all of the studies on ex-gay therapy have found that it doesn’t have any effective outcomeseven studies done by researchers who are trying to advocate for the practice.

Moreover, Doyle is attempting to reduce major medical organizations to “liberal trade organizations.” Perhaps he’s bitter on behalf of his partner Cohen, who was permanently expelled from the American Counseling Association for ethical violations in 2002. The American Psychological Association’s 2009 report and resolution against ex-gay therapy was based on a metastudy of 83 peer-reviewed studies from 1960–2007, and few of them were found to be methodologically sound. Among the key findings though were 1) that treatment doesn’t change orientation, 2) it does contribute to distress (through self-stigma, shame, isolation, and rejection), and 3) in contrast, clients whose sexual orientation was affirmed experienced a measurable benefit.

The only argument that Doyle has is that no research has disproven ex-gay therapy. Of course, science does not prove negatives, it just rules out hypotheses that don’t produce results. There is currently no research available disproving the idea that drinking lots of 7-Up cures an in-grown toenail, so perhaps Doyle should pursue some junk science that doesn’t propagate shame and rejection.


View the original article here

Monday, June 3, 2013

Why You Should Care About The Increasing Amount Of Fraud In Scientific Research

The Washington Post reported on the equivalent of an ongoing academic thriller unfurling at Johns Hopkins earlier this week, involving a researcher who alleges he was fired in retaliation for his criticism of flawed methodology — later used in an article published in Nature, one of most prestigious research journals — and the suicide of the primary author of the research while drafting a response to that criticism.

But while the full story remains to play out — Johns Hopkins refuses to comment and Nature has been quiet besides saying they expect to release a response in the future — this seedy tale can help bring one dark underbelly of the modern research world to light: How the academic politics of retraction and the pressure to publish may have an adverse effect on the quality of modern research.

A study published last year by Proceedings of the National Academy of Sciences noted that there has been a tenfold increase in scientific articles retracted due to fraud since 1975. Of the over 2000 biomedical and life-science retracted research articles studied, 21.3 percent of them were attributed to errors while 67.4 percent were due to researcher misconduct.  The Washington Post discussed the issue with one of the study’s authors, Ferric C. Fang:

“Fang said retractions may be rising because it is simply easier to cheat in an era of digital images, which can be easily manipulated. But he said the increase is caused at least in part by the growing competition for publication and for NIH grant money.

He noted that in the 1960s, about two out of three NIH grant requests were funded; today, the success rate for applicants for research funding is about one in five. At the same time, getting work published in the most esteemed journals, such as Nature, has become a “fetish” for some scientists, Fang said.”

While public funds support a majority of basic research in the U.S., those resources have been dwindling for years and took a significant hit in the sequester. That increase in competitiveness pressures researchers to present results, undoubtedly leading to some researchers falsifying their data in order to preserve their slice of the dwindling public research pie — also known as fraud. And when fraudulent research makes it through the publication process, it becomes part of the knowledge base built upon by other researchers around the world. For every fraudulent piece of research published, many more may rely on faulty grounding for future research projects, thus intellectually contaminating research areas with incorrectly drawn conclusions and impeding future advances.

The pitfalls of fraudulent research aren’t just theoretical: In the late 1990s, a medical researcher “misrepresented or altered the medical histories of all 12 of the patients” in a much-publicized study linking childhood vaccination to autism, in what some other researchers have called “the most damaging medical hoax of the last 100 years.” Between when the study was first came out and when it was disproved and retracted, there was a notable drop in youth vaccinations — which is bad for the health of our nation’s children, and the public at large.

Yet despite the severity of the problem and the great stakes at play, there is no centralized database to track these retractions — although new resources have emerged, like Retraction Watch, a blog run by two health journalists keeping tabs on the ongoing drama.


View the original article here

Wednesday, May 29, 2013

Family Research Council: Unmarried People Should Be Denied Birth Control And Punished For Having Sex

The right-wing Family Research Council — which uses its advocacy muscle to try to block comprehensive sexual health programs in public schools — is now going a step further, suggesting the young Americans who have premarital sex should be punished because they don’t deserve the right to engage in sexual intercourse.

According to senior FRC fellow Pat Fagan, the Supreme Court’s “first assault on marriage” was a 1972 case that overturned a state law banning unmarried people from purchasing birth control. Fagan claims that court decision effectively sanctioned premarital sex, “brushing aside thousands and thousands of years of wisdom, tradition, [and] culture.” Appearing on a radio show with Tony Perkins, the head of the organization, Fagan asserted that “society never gave young people that right,” and instead has an obligation to stop, punish, and shame that type of sexual behavior:

FAGAN: The court decided that single people have the right to contraceptives. What’s that got to do with marriage? Everything, because what the Supreme Court essentially said is single people have the right to engage in sexual intercourse. Well, societies have always forbidden that, there were laws against it. [...]

It’s not the contraception, everybody thinks it’s about contraception, but what this court case said was young people have the right to engage in sex outside of marriage. Society never gave young people that right, functioning societies don’t do that, they stop it, they punish it, they corral people, they shame people, they do whatever. The institution for the expression of sexuality is marriage and all societies always shepherded young people there, what the Supreme Court said was forget that shepherding, you can’t block that, that’s not to be done.

In fact, a full 80 percent of unmarried evangelical Christians report that they are having sex. Despite the emphasis on abstinence within the evangelical community — a misguided approach to sexuality that typically shames young adults about their bodies, ignores the existence of the LGBT community, and fails to equip adolescents with the resources they need to effectively manage their sexual health — it’s clear that premarital sex is the norm, not something that threatens the very fabric of modern society.

And ignoring the reality that teens are having sex has had serious consequences across the country. The states that push ineffective abstinence-only health classes have higher rates of teen pregnancy, higher rates of STDs, and higher concentrations of HIV infections. Even the evangelical community itself has started to realize that denying teens sexual health resources isn’t working, and has begun to move in the direction of supporting contraception and sex education.

The United States’ teen birth rate has actually recently plunged to a record low — but that wouldn’t be the case if Fagan had his way and unmarried Americans were denied access to birth control. According to the Guttmacher Institute, that decline in unintended teen pregnancies is “almost exclusively” the result of more young people using contraception.

(HT: Right Wing Watch)


View the original article here

Friday, May 17, 2013

Merck veteran named research chief, after drug setbacks

By Ransdell Pierson

March 7 (Reuters) - Merck & Co will bring back one of its veterans to head research and development, replacing retiring Peter Kim, who leaves behind a mixed record over the past decade at the drugmaker's highly respected laboratories.

Merck, after recent setbacks for some of its most important experimental drugs, said former Amgen Inc research chief Roger Perlmutter will take over from Kim on April 15, although Kim will stay on as a company advisor until August.

The appointment represents a homecoming for Perlmutter, who joined Amgen in February 2001 after four years with Merck, where he oversaw global basic research and preclinical development. While at Amgen sales of its Epogen and Aranesp anemia drugs plunged due to safety concerns.

Perlmutter left Amgen in February 2012 and has served since then as a board member of several smaller biotech companies.

But Perlmutter helped Amgen branch out into new areas, including successful development of Prolia for osteoporosis and Sensipar, used to treat dangerously high calcium levels in the blood.

Perlmutter became Amgen's research chief only months after Kim, then a 42-year-old professor at the Massachusetts Institute of Technology, was selected to head of research at Merck.

Merck has had several big successes under Kim's watch, including development of its blockbuster Januvia diabetes medicine and its Isentress treatment for HIV. But more recently, it has been hurt by failed trials of cholesterol treatment Tredaptive and migraine drug telcagepant, and a regulatory delay for a new type of osteoporosis medicine called odanacatib.

Merck's Vioxx arthritis drug was recalled in 2004 after being linked to heart attacks and strokes, forcing Kim to defend controversial clinical trials of the pill that were conducted before his arrival.

New medicines are badly needed at Merck, where sales of its onetime $6 billion-a-year Singulair asthma drug are plunging due to generic competition and other medicines will soon face cheaper generics. Moreover, cost savings from Merck's 2009 purchase of rival Schering Plough have mostly dried up and are no longer able to boost company earnings.

"On balance, most investors we speak with have been disappointed by Peter Kim's tenure as head of Merck's R&D," Leerink Swann analyst Seamus Fernandez said in a research note on Thursday.

"We believe a transition makes sense at this time." Fernandez said he believed Perlmutter's 10-year tenure at Amgen, the world's biggest biotechnology company, were "constructive. Overall he strikes us as a thoughtful straight shooter and a decisive leader."

Merck praised Kim's tenure. "His contributions have positioned us well for future success."

Shares of Merck were down nearly 1 percent in afternoon trading on the New York Stock Exchange.

(Reporting By Ransdell Pierson; editing by Carol Bishopric)

((ransdell.pierson@thomsonreuters.com)(646 223 6030)(Reuters Messaging: ransdell.pierson.thomsonreuters.com@reuters.net))

Keywords: MERCK PERLMUTTER/


View the original article here

Wednesday, May 1, 2013

White House Announces Plan To Open Up Access To Research Supported by Federal Funds

Office of Science and Technology Policy Director John Holdren

Today, the White House released a memo directing federal agencies to make publicly funded research available to the people who pay for it:

“The Office of Science and Technology Policy (OSTP) hereby directs each Federal agency with over $100 million in annual conduct of research and development expenditures to develop a plan to support increased public access to the results of research funded by the Federal Government.”

The directive is similar to the Fair Access to Science and Technology Research Act (FASTR), a recent bi-partisan legislative proposal aimed at opening up access to federally funded research, although the waiting twelve month waiting period before research is made available in the White House plan is twice the length of the six month delay suggested by FASTR. Both the White House plan and FASTR build upon the success of the National Institute of Health’s 2008 public access policy.

Dr. John Holdren, Director of the White House Office of Science and Technology Policy, thanked signers of a We The People petition calling for the reform, saying its popularity was “important to our discussions of this issue.”

Today’s announcement could be critical to addressing the broken for profit academic publishing system that has led to a flourishing open access movement in scholarly circles. The movement gained a new public spotlight following the suicide of activist Aaron Swartz while facing prosecution for what many believe was an attempt to liberate research from the closed academic database JSTOR.


View the original article here

Tuesday, April 16, 2013

The Other Aaron’s Law: How FASTR Could Help Americans Access The Research They Paid For

Just over a month after internet folk hero and activist Aaron Swartz ended his own life, a bipartisan group of law-makers have introduced legislation that would make progress on a cause near and dear to his heart: Open access to publicly funded research. The Fair Access to Science and Technology Research Act (FASTR), introduced this week by Reps. Zoe Lofgren (D-CA), Mike Doyle (D-PA), and Kevin Yoder (R-KS) in the House and Senators John Cornyn (R-TX) and Ron Wyden (D-OR) in the Senate, “require[s] federal agencies with annual extramural research budgets of $100 million or more to provide the public with online access to research manuscripts stemming from funded research no later than six months after publication in a peer-reviewed journal,” building on the success of the National Institutes of Health’s (NIH) 2008 public access policy.

Swartz faced a maximum sentence of decades in prison at the time of his death for charges related to his alleged downloading of nearly 5 million documents from the academic database JSTOR, in what many believe was an attempt to release the data. While efforts to reform the Computer Fraud and Abuse Act (CFAA), the law Swartz was being prosecuted under, using the moniker “Aaron’s Law” emerged quickly, the introduction of FASTR is the first legislative effort since his death to address the open access movement — the effort to provide unrestricted access to peer-reviewed research online.

Here’s how academic publishing works: Research is largely done by members of university communities (frequently funded by the public) who submit research to journals for publication (sometimes paying for the privilege). Then journals send the research back out to other academics to be edited blind (usually pro-bono), and the journal’s (often for profit) publishers sell back access to the published research to university libraries.

While the largest of the for-profit academic publishers, Elsevier, made $1.1 billion in profits in 2011 with a profit margin of around 35 percent, libraries have struggled to afford rising subscription costs that drove up expenditures by a staggering 273 percent between 1986 and 2004. The Harvard Faculty Council released a statement on the crisis last year noting that the prices for online content from two major providers increased by around 145 percent over the last six years alone, saying “[m]any large journal publishers have made the scholarly communication environment fiscally unsustainable and academically restrictive.”

FASTR is not an outright solution to this broken system, but it is a substantive step in the right direction that would provide open access because academic federal funding is the primary source of basic research support in the U.S. (the majority of which is carried out by academic institutions). And there are signs that the open access movement is making dents in the the academic publishing industry’s armor, like JSTOR’s Register & Read program. Neither that limited concession or FASTR will fully bring about the world of free information Swartz envisioned, but taken together they are a sign that world is slowly moving in the right direction.


View the original article here

Sunday, March 24, 2013

Tony Perkins Still Believes SPLC Motivated Shooter At Family Research Council

Earlier today, Floyd Lee Corkins pleaded guilty to several counts relating to when he opened fire at the Family Research Council, injuring a guard before he was subdued. FRC’s Tony Perkins used that news to reiterate his belief that by labeling groups like his as “hate groups,” the Southern Poverty Law Center gave Corkins a “license” for violence:

PERKINS: The day after Floyd Corkins came into the FRC headquarters and opened fire wounding one of our team members, I stated that while Corkins was responsible for the shooting, he had been given a license to perpetrate this act of violence by groups like the Southern Poverty Law Center which has systematically and recklessly labeled every organization with which they disagree as a “hate group.”

Today both assertions were validated in court as Corkins plead guilty to multiple criminal charges, including terrorism. The Southern Poverty Law Center can no longer say that it is not a source for those bent on committing acts of violence.  Only by ending its hate-labeling practices will the SPLC send a message that it no longer wishes to be a source for those who would commit acts of violence that are only designed to intimidate and silence Christians and others who support natural marriage and traditional morality.

Once again, I call on the SPLC to put an immediate stop to its practice of labeling organizations that oppose their promotion of homosexuality. Whether the SPLC continues to demonize those who hold to biblical morality or not, the Family Research Council will remain unequivocally committed to our mission of advancing faith, family and freedom.

Perkins’ accusation is just as “outrageous” now as it was back in August. The SPLC is simply identifying “hate” as “hate.” Contrary to Perkins’ implication, hate crimes based on sexual orientation increased in 2011 despite the fact that the overall number of hate crimes declined. Of course, he never takes responsibility for the rhetoric FRC puts forth everyday, such as this morning when he reminded the world that he believes gay men are pedophiles, despite claiming to say the opposite. In September, just moments after once again painting FRC as a victim to the SPLC, Perkins then compared homosexuality to drug abuse. It’s not hard to draw a connection between that kind of hateful rhetoric and the ongoing harassment of the LGBT community, but FRC’s “mission of advancing faith, family, and freedom” is not particularly concerned with reality.

The National Organization for Marriage, which is not itself identified as an anti-gay hate group by the SPLC, also issued a statement attacking the labels. According to Brian Brown, “irresponsible ‘hate group’ charges nearly led to a massacre at the Family Research Council.”


View the original article here

Monday, March 18, 2013

Denial River: Conspiracy Thinking In The Climate Blogosphere In Response To Research On Conspiracy Thinking

By Prof. Stephan Lewandowsky via Shaping Tomorrow’s World

There is growing evidence that conspiratorial thinking, also known as conspiracist ideation, is often involved in the rejection of scientific propositions. Conspiracist ideations tend to invoke alternative explanations for the nature or source of the scientific evidence. For example, among people who reject the link between HIV and AIDS, common ideations involve the beliefs that AIDS was created by the U.S. Government.

My colleagues and I published a paper recently that found evidence for the involvement of conspiracist ideation in the rejection of scientific propositions—from climate change to the link between tobacco and lung cancer, and between HIV and AIDS—among visitors to climate blogs. This was a fairly unsurprising result because it meshed well with previous research and the existing literature on the rejection of science. Indeed, it would have been far more surprising, from a scientific perspective, if the article had not found a link between conspiracist ideation and rejection of science.

Nonetheless, as some readers of this blog may remember, this article engendered considerable controversy.

The article also generated data.

Data, because for social scientists, public statements and publically-expressed ideas constitute data for further research. Cognitive scientists sometimes apply something called “narrative analysis” to understand how people, groups, or societies are organized and how they think.

In the case of the response to our earlier paper, we were struck by the way in which some of the accusations leveled against our paper were, well, somewhat conspiratorial in nature. We therefore decided to analyze the public response to our first paper with the hypothesis in mind that this response might also involve conspiracist ideation. We systematically collected utterances by bloggers and commenters, and we sought to classify them into various hypotheses leveled against our earlier paper. For each hypothesis, we then compared the public statements against a list of criteria for conspiracist ideation that was taken from the previous literature.

This follow-up paper was accepted a few days ago by Frontiers in Psychology, and a preliminary version of the paper is already available, for open access, here.

The title of the paper is Recursive fury: Conspiracist ideation in the blogosphere in response to research on conspiracist ideation, and it is authored by myself, John Cook, Klaus Oberauer, and Michael Marriott.

I enclose the abstract below:

Conspiracist ideation has been repeatedly implicated in the rejection of scientific propositions, although empirical evidence to date has been sparse. A recent study involving visitors to climate blogs found that conspiracist ideation was associated with the rejection of climate science and the rejection of other scientific propositions such as the link between lung cancer and smoking, and between HIV and AIDS (Lewandowsky, Oberauer, & Gignac, in press; LOG12 from here on). This article analyzes the response of the climate blogosphere to the publication of LOG12. We identify and trace the hypotheses that emerged in response to LOG12 and that questioned the validity of the paper’s conclusions. Using established criteria to identify conspiracist ideation, we show that many of the hypotheses exhibited conspiratorial content and counterfactual thinking. For example, whereas hypotheses were initially narrowly focused on LOG12, some ultimately grew in scope to include actors beyond the authors of LOG12, such as university executives, a media organization, and the Australian government. The overall pattern of the blogosphere’s response to LOG12 illustrates the possible role of conspiracist ideation in the rejection of science, although alternative scholarly interpretations may be advanced in the future.

– Stephan Lewandowskyos Winthrop Professor at the School of Psychology, University of Western Australia. He has published nearly 140 papers, chapters, and scholarly books on how people remember and think. He received a “Discovery Outstanding Researcher Award” from the Australian Research Council in 2011.

jQuery(document).ready(function(){jQuery('#comment_submit').click(function(){if(jQuery('#comment_check:checked').length

View the original article here

Saturday, February 2, 2013

Presidential Memorandum -- Engaging in Public Health Research on the Causes and Prevention of Gun Violence

The White House

Office of the Press Secretary

MEMORANDUM FOR THE SECRETARY OF HEALTH AND HUMAN SERVICES

SUBJECT: Engaging in Public Health Research on the Causes and Prevention of Gun Violence

In addition to being a law enforcement challenge, gun violence is also a serious public health issue that affects thousands of individuals, families, and communities across the Nation. Each year in the United States there are approximately 30,000 firearm-related deaths, and approximately 11,000 of those deaths result from homicides. Addressing this critical issue requires a comprehensive, multifaceted approach.

Recent research suggests that, in developing such an approach, a broader public health perspective is imperative. Significant strides can be made by assessing the causes of gun violence and the successful efforts in place for preventing the misuse of firearms. Taking these steps will improve our understanding of the gun violence epidemic and will aid in the continued development of gun violence prevention strategies.

Therefore, by the authority vested in me as President by the Constitution and the laws of the United States of America, I hereby direct the following:

Section 1. Research. The Secretary of Health and Human Services (Secretary), through the Director of the Centers for Disease Control and Prevention and other scientific agencies within the Department of Health and Human Services, shall conduct or sponsor research into the causes of gun violence and the ways to prevent it. The Secretary shall begin by identifying the most pressing research questions with the greatest potential public health impact, and by assessing existing public health interventions being implemented across the Nation to prevent gun violence.

Sec. 2. General Provisions. (a) Nothing in this memorandum shall be construed to impair or otherwise affect:

(i) the authority granted by law to an executive department or agency, or the head thereof; or

(ii) the functions of the Director of the Office of Management and Budget relating to budgetary, administrative, or legislative proposals.

(b) This memorandum shall be implemented consistent with applicable law and subject to the availability of appropriations.

(c) This memorandum is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.

Sec. 3. Publication. You are hereby authorized and directed to publish this memorandum in the Federal Register.

BARACK OBAMA

Watch Hinna, Taejah, Julia and Grant read the letters they wrote to President Obama, asking him to do something about gun violence.

Regional Round Up: Now is the Time

Editorial pages across the country today are lauding the President’s broad approach to address curbing gun violence in our nation

Learn more about the new Health Insurance Marketplace, which will kick in come October and mark the beginning of new health insurance and tax credits for millions of Americans.

view all related blog posts

View the original article here

Presidential Memorandum -- Engaging in Public Health Research on the Causes and Prevention of Gun Violence

The White House

Office of the Press Secretary

MEMORANDUM FOR THE SECRETARY OF HEALTH AND HUMAN SERVICES

SUBJECT: Engaging in Public Health Research on the Causes and Prevention of Gun Violence

In addition to being a law enforcement challenge, gun violence is also a serious public health issue that affects thousands of individuals, families, and communities across the Nation. Each year in the United States there are approximately 30,000 firearm-related deaths, and approximately 11,000 of those deaths result from homicides. Addressing this critical issue requires a comprehensive, multifaceted approach.

Recent research suggests that, in developing such an approach, a broader public health perspective is imperative. Significant strides can be made by assessing the causes of gun violence and the successful efforts in place for preventing the misuse of firearms. Taking these steps will improve our understanding of the gun violence epidemic and will aid in the continued development of gun violence prevention strategies.

Therefore, by the authority vested in me as President by the Constitution and the laws of the United States of America, I hereby direct the following:

Section 1. Research. The Secretary of Health and Human Services (Secretary), through the Director of the Centers for Disease Control and Prevention and other scientific agencies within the Department of Health and Human Services, shall conduct or sponsor research into the causes of gun violence and the ways to prevent it. The Secretary shall begin by identifying the most pressing research questions with the greatest potential public health impact, and by assessing existing public health interventions being implemented across the Nation to prevent gun violence.

Sec. 2. General Provisions. (a) Nothing in this memorandum shall be construed to impair or otherwise affect:

(i) the authority granted by law to an executive department or agency, or the head thereof; or

(ii) the functions of the Director of the Office of Management and Budget relating to budgetary, administrative, or legislative proposals.

(b) This memorandum shall be implemented consistent with applicable law and subject to the availability of appropriations.

(c) This memorandum is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.

Sec. 3. Publication. You are hereby authorized and directed to publish this memorandum in the Federal Register.

BARACK OBAMA

Watch Hinna, Taejah, Julia and Grant read the letters they wrote to President Obama, asking him to do something about gun violence.

Regional Round Up: Now is the Time

Editorial pages across the country today are lauding the President’s broad approach to address curbing gun violence in our nation

Learn more about the new Health Insurance Marketplace, which will kick in come October and mark the beginning of new health insurance and tax credits for millions of Americans.

view all related blog posts

View the original article here

Wednesday, January 16, 2013

Supreme Court Allows Assault On Stem Cell Research To Die

Two years ago, Reagan-appointed Chief Judge Royce Lamberth suspended all federal funding for embryonic stem cell research in a sweeping opinion that even invalidated funding permitted under President George W. Bush’s policies. Despite the fact that the Clinton, Bush and Obama Administrations all agreed that Judge Lamberth misinterpreted federal law, Lamberth relied on a federal law forbidding funding of “research in which a human embryo or embryos are destroyed” to hold that federal spending not only cannot fund the destruction of a new embryo, it also cannot fund research that builds on past research that resulted in the destruction of an embryo.

Lamberth’s decision was eventually reversed by a conservative panel of the United States Court of Appeals for the District of Columbia Circuit. The appeals court held, correctly, that even though Lamberth might have proposed a plausible reading of federal law, longstanding Supreme Court precedent generally requires courts to defer to an agency’s reading of a statute. As the appeals court explained, “the plaintiffs are unlikely to prevail because Dickey-Wicker is ambiguous and the NIH seems reasonably to have concluded that, although Dickey-Wicker bars funding for the destructive act of deriving an [embryonic stem cell] from an embryo, it does not prohibit funding a research project in which an [embryonic stem cell] will be used.” Yesterday, the Supreme Court announced it would not hear this case, effectively killing this challenge to stem cell research.

This is an important victory for science, and it is just as much a victory for judicial restraint. As the near-success of the Affordable Care Act lawsuits demonstrate, conservative judges and justices are increasingly willing to substitute their policy preferences for the law, even when they must rely on legal theories that, in the words of one of the nation’s most conservative judges, have no basis “in either the text of the Constitution or Supreme Court precedent.” The requirement that judges defer to agencies in interpreting ambiguous statutes is an important check on the judiciary’s ability to impose their policy views on the nation. Agency leaders change with each presidential election; judges do not. And so the power to interpret a genuinely ambiguous statute should rest with officials whose legitimacy flows more closely from the will of the people.


View the original article here

Tuesday, January 8, 2013

Drug-Resistant Malaria Flares As Funding For Research Tapers

Global health experts worry that a new breed of malaria that has arisen in South Asia could reverse trends in the fight against the disease, since it has proven resistant to the drugs usually used to treat malaria infections.

Cases of malaria are currently treated with a drug called artemisinin, which typically clears the Plasmodium parasite that causes malaria’s symptoms from humans within about 24 hours. However, a new strain of the disease has sprung up on the Thailand-Myannmar border that has shown the ability to cling to its host for three days or more after the administration of treatment. Should this form of malaria spread, the results could be catastrophic:

We know what will happen in Africa when resistance is bad because we’ve been there before in the 1990s with chloroquine (another anti-malarial drug) … millions of deaths,” [malaria researcher Dr Francois Nosten] warned.

“We must prevent artemisinin resistance reaching Africa, but we also need to control it for the people in Asia – for their future.”

Twenty years passed between the evolution of a strain of malaria resistant to the then-prevelant treatment of choloroquine in the same South Asian region before it migrated to Africa. While the disease does eventually fall to arteminsin treatment still, the inability of the patient to find relief from malaria’s high fevers is likely to raise the mortality rate among those infected with the new strain. In 2010, malaria caused the deaths of an estimated 660,000 people, with Africa having the highest infection rate of any continent.

That number has fallen in recent years, thanks to a concerted effort to halt the spread of malaria and other diseases by programs such as the Global Fund and the United States’ PEPFAR. However, the gains that have been made since a funding surge from 2004-2009 are proving fragile as budgets have leveled off. The World Health Organization’s World Malaria Report 2012 warned of the potential for backsliding as funding for anti-malarial bed nets, the best prevention for infection, has frozen.

Researchers in the region continue to strive towards new and improved drugs to treat malaria amid the uptick in new cases. Whether the research will yield results in time to halt the progress of new malarial strains is yet to be seen.


View the original article here

Wednesday, December 26, 2012

The Affordable Care Act’s Rulemaking Process: What the Research Shows

Abstract: The rush to issue regulations for implementing the most popular parts of the President’s health insurance bill resulted in eight “economically significant” regulations of remarkably poor quality, according to Jerry Ellig of the Mercatus Center at George Mason University and Christopher Conover of Duke University. They detailed major deficiencies in the regulatory process, including poor analysis, inadequate cost–benefit analysis, a bias toward regulatory solutions, and a failure to consider alternatives. The authors suggest that the “interim final rulemaking” process used to promulgate these regulations contributes to the problem, much as it did when the Department of Homeland Security used the same process to issue final rules after the 9/11 terrorist attacks.

The Patient Protection and Affordable Care Act of 2010 (the Affordable Care Act or ACA), heralded as President Barack Obama’s signature achievement, is intended to reform and expand health insurance coverage. Despite its 906 pages of statutes covering topics from tanning booths to individual and employer mandates for insurance purchases, the scope of regulation—not merely the statutory language—will determine how the law is understood, enforced, and implemented.

The Secretary of Health and Human Services (HHS) is chiefly responsible for developing the ACA’s body of regulation. While most major ACA regulations, such as the requirements on employers, do not take effect until 2014, HHS is already putting many regulations into place. The government has promulgated final rules and proposed rules and has generated hundreds of guidance documents, frequently asked questions, forms, letters, and other sub-regulatory documents that clarify or refine the rules.

Thus far, the most extensive academic examination of this body of regulation is “Beware the Rush to Presumption,” a series of three research papers by Jerry Ellig of the Mercatus Center at George Mason University and Christopher Conover of Duke University.[1] Their analyses focus on the process used to craft the ACA regulations, and detail major deficiencies in that process, compared with other regulatory initiatives. In their review of eight “economically significant” ACA regulations[2] promulgated in 2010, Ellig and Conover reveal some key findings. First, agency analysis was often inadequate, falling short of the quality of analysis normally used by HHS and other agencies. Moreover, presidential and congressional politics and pressure heavily influenced the ACA regulatory process.

HHS issued the eight economically significant regulations as “interim final rules.” Interim final rulemaking is an expedited process in which rules are created without the normal notice and comment period. Interim final rulemaking is permitted under the Administrative Procedure Act (APA) if normal notice and comment rulemaking is “impractical, unnecessary, or contrary to the public interest” and is often invoked because of tight legislative deadlines.[3] Economically significant regulations are generally subject to a more rigorous rulemaking, including detailed cost–benefit analysis and reviewing alternative means of achieving the legislative goals.

Biased Analysis

Ellig and Conover found incomplete agency analyses that were insufficient to inform decision making. According to the authors, the result is a bias favoring regulation, based on both underestimated costs and overestimated benefits. In developing the proposed regulations, agency products exhibited a conspicuous lack of alternative approaches.

The overall effect of this bias favoring regulation was substantial. For example, for children with pre-existing medical conditions, the agency overstated the rule’s benefits by a factor of three to five, based on the experience of state high risk pools. The pre-existing condition insurance plan overstated the reduction in bankruptcy risk by as much as a factor of eight, a result of overestimating the percentage of bankruptcies related to medical expense and including cases of medical expense–related bankruptcies by the insured. Likewise, Ellig and Conover estimated Early Retirement Reinsurance costs at $9.2 billion to $10 billion over four years versus HHS estimates of $39.8 million. Similarly, they estimated that dependent coverage for children up to age 26 would cost $0.9 billion to $1 billion annually versus the HHS estimate of $10.4 million.

Furthermore, multiple analytical inadequacies skewed the agency analysis. For instance, federal regulators failed to make the important distinction between “transfers” and “efficiency benefits.” While an efficiency benefit creates cost savings, a transfer simply moves existing resources from some individuals to others. For example, “uncompensated care” is a transfer because the current system already absorbs the cost. The new regulation only changes the source of funding; it does not reduce costs.

Nor did regulators consider the “crowding out” of existing health coverage, which can have a substantial effect according to the authors. In the Early Retirement Reinsurance Program, the ACA could subsidize plans that would have existed without the subsidy.[4] The authors note that the failure to consider these transfers undercuts the regulators’ ability to assess the equity of these transfers.

Equity Issues

The authors also contend that the regulators’ assumption that early retirees may have a difficult time obtaining insurance due to age and medical condition implies an equity problem. Yet the regulators did not explore the issue beyond this assumption. An equity problem is suggested by the assumption that insured people had been paying what the regulators call a “hidden tax” to cover the uninsured, although the analysis does not clearly indicate how making this tax explicit solves the equity problem.

In other cases, the regulators merely stated or assumed that ACA regulations that remove the pre-existing condition limitations would produce “a meaningful improvement in equity.” Yet, as the authors point out, the ACA regulators do not define the term or explain how it was deemed “meaningful.”

Similar undefined benefits include “financial risk reduction,” “cost savings,” and “health benefits”—an odd oversight for a major health regulation affecting millions of Americans. Ellig and Conover discuss the availability of established methods to quantify such benefits. The regulators simply assert other ACA benefits without quantifying or explaining them. For example, preventive services are assumed to result in cost savings, a claim disputed by an extensive body of professional literature. Curiously, the regulators did not even address why insurance companies would not cover services that so clearly yield a cost savings.

Costs over Benefits

According to Ellig and Conover, when the understated costs and overstated benefits are corrected, three of the ACA regulations—early retirement reinsurance, dependent coverage up to 26, and pre-existing condition insurance plan—clearly fail a cost–benefit analysis. The correction also raises legitimate questions about whether the benefits actually exceed the costs for two other regulations: pre-existing condition limitations and coverage for preventive services.

The study finds that regulators failed to consider moral hazards, which result when people change behavior because they no longer bear all or any of the costs of their actions, such as the potential for health insurance to make a person more likely to participate in detrimental activities such as smoking and excessive drinking, knowing that insurance will pay for any needed medical treatment. Another form of moral hazard arises when people can use services in which the cost exceeds the benefit, such as going to an emergency room to treat a cold. Unnecessary medical expenses, the researchers note, account for 28 percent of Medicaid spending and for 10 percent of private insurance.[5]

Another component of sound regulatory analysis is an examination of regulatory alternatives, generally one more stringent and one less stringent than the preferred alternative. Ideally, Congress and the public should be informed of the alternatives. In the case of the ACA, HHS did not consider using the IRS definition of “dependent” for the extension of insurance coverage to dependent children up to 26. For preventive service coverage, HHS did not consider covering only those services likely to lead to cost savings or some specified cost per outcome, which could have greatly reduced the cost of preventive services coverage.

Comparative Performance

To ensure their review was not just an academic post hoc review detached from reality, the researchers compared the ACA rulemaking with other agency regulatory work. They found the analysis and the quality of the process fell below the standard agency work product under normal rulemaking conditions.[6] The 2010 ACA interim final rules scored substantially lower than previous HHS regulations. These lower scores are the result of incomplete analysis and limited use of that analysis in creating the regulation.

In their evaluation of the 2010 ACA regulations, the researchers ranked them on a scale of 0 to 60. Two ACA regulations received a score of 13, and the highest ranked ACA regulation received a score of 25—below the average score of previous years. HHS regulations averaged a score of 26 in 2009 and a score of 29 in 2008.[7]

The researchers found similarly low regulatory scores when they looked at the homeland security regulations developed and promulgated after September 11, 2001. These were another presidential priority enacted under a tight congressionally imposed deadline. For these rules, “the agency offered some pieces of theory or evidence but far from a comprehensive analysis.”[8]

Ellig and Conover conclude that “incomplete analysis may be a systematic result of presidential priorities and tight deadlines, rather than a problem unique to the health care regulation.”[9] To examine this hypothesis further, Ellig and Conover examined the role of presidential and congressional politics on the regulatory process.

Congressional Politics

The authors conclude that Congress often affects the quality and thoroughness of regulations by imposing deadlines. Congress may impose tight deadlines to ensure that a law and its enacting regulations are in place before an election or before new Members take office. Potential changes in composition of Congress and the congressional committees directly overseeing the federal regulators encourage tight deadlines to allow Congress to ensure that the resulting regulations reflect the legislative priorities.

Congress enacted the ACA in the face of public opposition: only 10 of nearly 140 polls between July 2009 and passage of the bill showed majority popular support. Between passage of the bill and August 10, 2011, only one of 87 polls opposed repeal. With the 2010 congressional elections only seven months away, Members of Congress had a clear incentive to put the more popular provisions of the law in place, in hopes that people would support the new law to keep these popular benefits.

Presidential Politics

The White House impact on federal regulatory action is routine. Based on the extensive and detailed formal directives issued by the Clinton and Bush Administrations, agencies often review regulations in light of presidential priorities. This “administrative presidency” model discourages independent agency analysis and limits review by the Office of Information and Regulatory Affairs (OIRA). Agency economists confirm that when presidential priorities create decisions that precede analysis, the subsequent analysis is nothing more than a document written to convince OIRA to approve the regulation.[10]

The ACA was a presidential priority. The President filled key Administration positions with ideological supporters of his ambitious health care agenda, and these key players were deeply involved in the process and championed aggressive executive authority. For example, months prior to the release of a rule, when a question arose about the meaning of the pre-existing condition exclusion for children under 19, HHS Secretary Kathleen Sebelius wrote a letter to a major health insurance industry group declaring a guaranteed issue requirement, even though the law did not require it until 2014.[11]

In short, ACA rules were produced under abbreviated procedures to comply with tight legislative deadlines and to satisfy presidential priorities. Historically, the rulemaking process is not a mere formality, but an opportunity for the agency to gather information. Shorter notice and comment periods, abbreviated OIRA review, and failure to fully analyze costs and benefits short-circuited the usual checks inherent in the process. It also eliminated opportunities for innovative solutions. The formal rulemaking process is designed to allow time for thorough and thoughtful analysis to produce appropriate regulations.

According to the authors, the poor quality of the ACA regulations resulted from tight congressionally imposed deadlines. Because the rules had high stakes for the White House, the federal regulators crafted analysis to support a decision rather than to assist policymakers in making an informed decision. These factors are not unique to the ACA. A similar convergence of presidential priority and congressional pressure resulted in similar procedural shortcuts for a series of interim final rules from the Department of Homeland Security after the 9/11 attacks.

Ellig and Conover conclude that this pattern demonstrates a need for additional procedural safeguards. In addition to reining in the use of interim final rulemaking, they suggest other procedural safeguards, such as requiring formal rulemaking within a specified period for regulations implemented as “interim final rules” or some system of external review of agency analyses.

Summary of Key Findings

The early and relatively minor provisions of the Affordable Care Act that Members of Congress believed would be popular took effect more quickly, but the shorter deadlines undermined the quality of the process. Major and more complex provisions of the law—such as the mandates on individuals, employers, and states—must meet deadlines for implementation in 2014.The agency analyses of the regulations that implement the early ACA provisions suffered from inadequate cost–benefit analysis and insufficient consideration of regulatory alternatives. Thus, these analyses failed to properly inform the regulatory decision-making process.The ACA regulatory process fell below the normal standards of HHS and other agencies in writing regulations.

Diane R. Calmus is a Graduate Fellow in the Center for Health Policy Studies at The Heritage Foundation.

[1]Christopher J. Conover and Jerry Ellig, “Beware the Rush to Presumption, Part A: Material Omissions in Regulatory Analyses for the Affordable Care Act’s Interim Final Rules,” George Mason University, Mercatus Center, Working Paper No. 12-1, January 9, 2012, http://mercatus.org/publication/beware-rush-presumption-part (accessed October 3, 2012); Jerry Ellig and Christopher J. Conover, “Beware the Rush to Presumption, Part B: Substandard Regulatory Analyses for the Affordable Care Act’s Interim Final Rules,” George Mason University, Mercatus Center, Working Paper No. 12-2, January 9, 2012, http://mercatus.org/publication/beware-rush-presumption-part-b (accessed October 3, 2012); and Christopher J. Conover and Jerry Ellig, “Beware the Rush to Presumption, Part C: Material Omissions in Regulatory Analyses for the Affordable Care Act’s Interim Final Rules,” George Mason University, Mercatus Center, Working Paper No. 12-3, January 9, 2012, http://mercatus.org/publication/beware-rush-presumption-part-b (accessed October 3, 2012).

[2]An economically significant regulation is defined as a regulation that has an economic impact greater than $100 million annually. William J. Clinton, “Regulatory Planning and Review,” Executive Order 12866, September 30, 1993, § 3 (f).The eight regulations are: (1) dependent coverage for children up to age 26; (2) pre-existing condition exclusions, limitations, etc.; (3) coverage of preventive services; (4) claims appeals and external review process; (5) medical loss ratio requirement; (6) grandfathered health plans; (7) early retirement reinsurance program; and (8) pre-existing condition insurance program.

[3]5 U.S. Code §§ 553(d)(3), 808(2). Interim final rules are promulgated 50 percent more often when there is a legislative deadline, as with the 2010 health care regulations.

[4]The crowd-out phenomenon can have a substantial impact. For example, it is suggested to account for 75 percent of the Medicare Part D spending. Gary V. Engelhardt and Jonathan Gruber, “Medicare Part D and the Financial Protection of the Elderly,” National Bureau of Economic Research Working Paper No. 16155, July 2010, http://www.nber.org/papers/w16155 (accessed October 4, 2012).

[5]Amy Finkelstein and Robin McKnight, “What Did Medicare Do (and Was It Worth It)?” National Bureau of Economic Research Working Paper No. 11609, September 2005, http://www.nber.org/papers/w11609 (accessed October 4, 2012), and Emmet B. Keeler et al., “The Demand for Episodes of Medical Treatment in the Health Insurance Experiment,” RAND Corporation, March 1988, http://www.rand.org/pubs/reports/2006/R3454.pdf (accessed October 4, 2012).

[6]The comparison included all proposed economically significant regulation during the Bush Administration in 2008 and the Obama Administration in 2009, based on previous scoring by the Mercatus Center’s Regulatory Report Card project. Additionally, the Department of Homeland Security (DHS) issued economically significant interim final rules in the wake of the terrorist attacks on September 11, 2001. Like the ACA regulations, the DHS rules were created under tight congressionally imposed deadlines and were a presidential priority.

[7]The comparison used the Mercatus Center’s Report Card method, which scores regulations on 12 criteria grouped into three categories: openness, analysis, and use. Each criterion is scored on a scale of 0 (no useful content) to 5 (comprehensive analysis with potential best practices), for a total possible score of 60. The comparison did not include budget regulations, which score extremely low across the board. The 2010 health care regulations classified as budget regulations received scores not substantially different from the abysmal 2008–2009 budget regulation scores. This method attempts to ensure that the rule makers reasonably covered the major elements of regulatory analysis and provided enough information for a reader to review and verify the method, data, and result. This method closely parallels the Office of Information and Regulatory Affairs checklist of November 2010 because both are based on the direction presented in Executive Order 12866 and Office of Management and Budget Circular A-4. William J. Clinton, “Regulatory Planning and Review,” and Office of Management and Budget, “Regulatory Analysis,” Circular A-4, September 17, 2003, http://www.whitehouse.gov/omb/circulars_a004_a-4 (accessed October 4, 2012).

[8]Ellig and Conover, “Beware the Rush to Presumption, Part B,” p. 21.


View the original article here